Yanwei Technology
衍微科技
Yanwei Technology (衍微科技) is a synthetic biology company in FreeS Fund's biotech portfolio. Per FreeS Capital's reporting, it raised a RMB 50 million angel round in mid-2022 co-led by FreeS and Sequoia China , and completed a new funding round in early 2025 as part of FreeS's ongoing bet on bio-manufacturing . FreeS groups Yanwei with peers like Bluepha Microbiology, Heliosyntek, and SiCure in an "AI4S" thesis—using AI to drive scientific discovery across materials science, brain-computer interfaces, and bio-manufacturing . elsewhere's corpus does not cover Yanwei's specific products or founding team in detail.
AI-generated — may contain errors, please verify.
Coverage
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
峰瑞资本·7 Interdisciplinary Companies Close New Funding Rounds | FreeS Family Funding News Vol.22
Looking forward to working alongside more outstanding founders.
峰瑞资本·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·The U.S.-China Biotech Race: Where Are the Opportunities in Synthetic Biology? | FreeS Fund Dialogue
Over the next five to ten years, which technologies will have a significant impact on synthetic biology?
峰瑞资本·Taking the Next Step This Summer: 7 Companies Announce Funding | FreeS Family Funding News · Vol 11
Walk alongside more outstanding founders.
峰瑞资本·
